IMPACT BIOMEDICAL INC. (IBO)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$16.7M
Stockholders' Equity
$10.8M
Cash & Equivalents
$10,000
Long-Term Debt
—

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, IMPACT BIOMEDICAL INC. reported revenue of $3,000, net income of -$699,000, and total assets of $16.7M. Every figure below is taken directly from IMPACT BIOMEDICAL INC.'s SEC filings: each links to the source document on EDGAR.

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025$32,000-$11.8M
FY2024—-$24.7M
FY2023—-$4.3M
FY2022$50,000-$7.3M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KOct 9, 2026on EDGAR ↗
8-KSep 16, 2026on EDGAR ↗
8-KSep 14, 2026on EDGAR ↗
10-QAug 7, 2026on EDGAR ↗
10-QMay 12, 2026on EDGAR ↗
10-KMar 11, 2026on EDGAR ↗
8-KMar 4, 2026on EDGAR ↗
10-QNov 7, 2025on EDGAR ↗
8-KNov 6, 2025on EDGAR ↗
8-KOct 27, 2025on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$16.7Msource ↗
Stockholders’ Equity$10.8Msource ↗
Cash & Equivalents$10,000source ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue$3,000source ↗
Net Income-$699,000source ↗
Operating Income-$702,000source ↗
Gross Profit$2,000source ↗
Cost of Revenue$1,000source ↗
R&D Expense$76,000source ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)$-0.01source ↗
EPS (basic)$-0.01source ↗
Shares Outstanding107.8Msource ↗
Cash from Operations$470,000source ↗
Cash from Financing—source ↗
Cash from Investing$2,000source ↗

Insider activity

Form 4 open-market activity, last 180 days

Buys
0
Sells
3
Net shares
-906

Restatement history

Point-in-time

5 of 97 annual fact-keys were materially restated between filings: what IMPACT BIOMEDICAL INC. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

See the restatement detail →

Deeper fundamentals

A free API key reaches IBO’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Get a free API key →See plans

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/IBO

MCP tool: get_sec_fundamentals ticker=IBO

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/IBO/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=IBO as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/IBO/history

MCP tool: get_fundamentals_history ticker=IBO

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/financial-health/IBO

MCP tool: get_financial_health ticker=IBO

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.